Patent SG-11201809716V-A (SG)
Title: T-CELL RECEPTORS WHICH RECOGNISE FRAMESHIFT MUTANTS OF TGFßRII
Inventor: INDERBERG ELSE MARIT
IPC: C07K14/725
Filed: 2017-05-09
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111111111111101011111111111 011101111101111111111111111111111111011110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2017/194555 Al 16 November 2017 (16.11.2017) WIPO I PCT (51) International Patent Classification: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, C07K 14/725 (2006.01) C07K 14/495 (2006.01) KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: PCT/EP2017/061087 Published: — with international search report (Art. 21(3)) (22) International Filing Date: — with sequence listing part of description (Rule 5.2(a)) 09 May 2017 (09.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1608052.5 09 May 2016 (09.05.2016) GB (71) Applicant: OSLO UNIVERSITETSSYKEHUS HF [NO/NO]; PO Box 4950, Nydalen, 0424 Oslo (NO). (72) Inventors: INDERBERG, Else Marit; Nedre Skoyen vei 20, 0276 Oslo (NO). GAUDERNACK, Gustav; An- thon Walles vei 17A, 1337 Sandvika (NO). WALCHLI, Sebastien; Nedre Skoyen vei 20, 0276 Oslo (NO). KVAL- HEIM, Gunnar; Asstubben 13, 0381 Oslo (NO). Agent: DEHNS; St Bride's House, 10 Salisbury Square, London Greater London EC4Y 8JD (GB). (74) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (81) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (84) ,_ 1 (54) Title: T-CELL RECEPTORS WHICH RECOGNISE FRAMESHIFT MUTANTS OF TGFBRII (57) : The present invention relates to TCR molecules which recognise neopeptides produced as a result of the cancer-associ- in ated \"-1A\" frameshift mutation in human TGFI3RII. The TCR molecules are capable of binding a peptide of SEQ ID NO: 1 when said in • in peptide i s presented by a Class I MHC, and comprise an a-chain domain and a (3-chain domain, each chain domain comprising three .. CDR sequences, wherein a) CDRs 1, 2 and 3 of the a-chain domain have the sequences of SEQ ID NOs: 2, 3 and 4 respectively; and b) 01 CDRs 1, 2 and 3 of the 0-chain domain have the sequences of SEQ ID NOs: 5, 6 and 7 respectively, and wherein one or more of said 1-1 --.... CDR sequences may optionally be modified by substitution, addition or deletion of 1 or 2 amino acids. Nucleic acid molecules encoding IN such TCRs are provided, as are soluble TCR molecules with these CDR sequences. The nucleic acid molecules of the invention can C 1-1 be used to modify immune effector cells to express a TCR as defmed herein, and such modified immune effector cells are useful in N therapy for cancer, as are soluble TCRs as defmed above. C